Physician profile
Rodolfo R Batarse
NPI 1417914193
$909,820.43
in general payments reported to CMS, 2019-2025
37 companies · $151K in 2025
The $151K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256K · 2020: $89K · 2021: $117K · 2022: $133K · 2023: $85K · 2024: $80K · 2025: $151K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $182K · Travel and Lodging: $65K · Honoraria: $42K · Food and Beverage: $14K · Consulting Fee: $12K · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $182,394.00 |
| Travel and Lodging | $64,766.32 |
| Honoraria | $41,838.42 |
| Food and Beverage | $14,177.57 |
| Consulting Fee | $11,663.50 |
| Education | $209.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $146,592.81 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $145,533.91 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $144,862.63 | 2021-2025 | |
| Vifor Pharma, INC. | $134,866.00 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $128,203.08 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Ardelyx, INC. | $63,864.97 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Mallinckrodt Hospital Products INC. | $42,273.08 | 2020-2025 | Acthar, Amitiza, Terlivaz |
| Mallinckrodt Enterprises LLC | $31,891.03 | 2019 | |
| Akebia Therapeutics INC | $30,559.73 | 2019-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals Lp | $18,325.49 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $13,947.01 | 2022-2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $3,570.00 | 2019-2021 | |
| Horizon Therapeutics Plc | $2,133.64 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $608.16 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $541.85 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $322.37 | 2019-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.93 | 2024-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $182.04 | 2019-2024 | Jynarque |
| Apellis Pharmaceuticals, INC. | $162.39 | 2025 | Empaveli |
| Opko Pharmaceuticals, LLC | $162.29 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $161.99 | 2022-2025 | Benlysta |
| Abbvie INC. | $124.55 | 2019 | |
| La Jolla Pharmaceutical Company | $93.14 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $84.29 | 2019 | |
| Amag Pharmaceuticals, INC. | $82.58 | 2019-2020 | |
| Veloxis Pharmaceuticals, INC. | $77.32 | 2025 | Envarsus |
| Novartis Pharmaceuticals Corporation | $75.44 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $57.28 | 2023-2025 | Purified Cortrophin Gel |
| Chiesi USA, INC. | $27.10 | 2024 | Elfabrio |
| Scpharmaceuticals INC. | $26.43 | 2025 | |
| Shire North American Group INC | $21.56 | 2019 | |
| Lilly USA, LLC | $21.56 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.68 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.76 | 2019 | |
| Novo Nordisk INC | $18.34 | 2025 | Ozempic |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Batarse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.